SulfadoxinePyrimethamine Combination in Congenital Toxoplasmosis
recent changes in palivizumab use guidelines. Although we find these comments from Dr. Ambrose (an employee of AstraZeneca, the manufacturers of palivizumab) provocative, we believe that a few points should be clarified.
Related to the point of causality, it is well-known that an observational study cannot, by nature, prove causality. Therefore, we direct the reader back to the fact that a power analysis simply gives the reader a frame of reference regarding the size of our study and an estimated difference able to be detected, if indeed one existed. Our power analysis should not be interpreted as a presumed result. We are very transparent that our study was the first real-world experience published to describe the impact of implementing the nationally recognized 2014 American Academy of Pediatrics (AAP) palivizumab guideline.
Dr. Ambrose states that the newly excluded patients from the most recent palivizumab guideline represent a small number of total US children. We do not disagree with this claim; however, we propose that this group represents both a more clinically and financially significant change in palivizumab usage than Dr. Ambrose's stated percentage may suggest. Moreover, the population of greater interest would be the relative percentage change of patients eligible for palivizumab in the US, not the percentage of total US children affected by individual guideline criteria. Our observed baseline dose rate of 21.7 doses per 1000 children <24 months represents an epidemiologically relevant rate for treatment in this population as a whole and would submit that our observed utilization decrease of nearly 50% represents a valid and valuable observation, especially when the numerical rate of respiratory syncytial virus (RSV) hospitalizations observed had changed only minimally (5.37-5.78/1000 children <24 months).
Dr. Ambrose cites a very dramatic number of RSV hospitalizations that the small percentage of children affected by these recent changes would need to incur to meet our specified level of statistical significance. We would direct Dr. Ambrose to the discussion portion of the article where this limitation is specifically addressed. The authors must also clarify the implausibility of recreating our study using only the birth cohort of children affected by this guideline change in a pre-post format. A study of that magnitude would require nearly every RSV hospitalization in the US for this affected group to be recorded. Additionally, in order for our observed difference of 0.41 hospitalizations per 1000 children to be due solely to the group affected by the guideline change, this would require an absolute increase of 53 hospitalizations per 1000 children, not 323. Our observed hospitalization rates are similar to or lower than previously recorded rates for both the general pediatric population and the rate for those affected by the guideline change for prematurity alone. 1 Thus, the clinical significance of our observed small change would be debatable compared with the highly significant decrease in palivizumab utilization and associated costs.
We trust that the AAP acts only in the best interest of their patients, with intent to do no harm both medically and economically. The aim of this study was primarily to quantify the impact of the guideline update at our institution; hospitalization rates and palivizumab utilization were the clearest markers to demonstrate change, if any would be seen. Our study provides a valuable look at institutional-level guideline implementation, as the cost of palivizumab can be devastating to both health systems and families of patients, particularly when evidence is conflicting or does not exist to show that palivizumab immunoprophylaxis would change the clinical outcome. 2 We feel our conclusions remain valid that the change in the guidelines did significantly reduce the use and thereby the cost of palivizumab treatment while not having a significant adverse impact on RSV hospitalization rate. The authors and our institution choose to support the outstanding work of the AAP who must help health systems provide both evidence-based and cost-effective care in the setting of our continued healthcare spending crisis.
To the Editors:
I n answer to the publication of Teil et al, 1 we are able to confirm these results in our experience of Reims Toxoplasmosis Group team and the absentia of badly hematologic impact on children treated for congenital toxoplasmosis (CT) with sulfadoxinepyrimethamine combination (Fansidar*).
Between 1978 and 2006, a total of 171 children born to 169 mothers who had contracted toxoplasmosis during pregnancy were diagnosed to CT. CT was diagnosed during pregnancy in 37 cases after prenatal positive diagnosis performed on fetal blood (10 cases) or on amniotic fluid (27 cases) (total: 21.5 %), leading administration of sulfadoxine-pyrimethamine (Fansidar*) in mothers. 2 When diagnosis was done after birth, CT was diagnosed during first month of life in 112 cases/134 (65.5%) and during the first year of life in 22 cases (13%) (median: 4 months), thus pulling the starting up of treatment with Fansidar*. 3 On the 171 children, only 146 were followed-up after birth by our group in Reims during more than 6 months survey; 35 (24%) were treated by sequential treatment including Fansidar* and spiramycin for 12 months (spiramycin 1 month every third month) (group A) and 110 (75.3%) by Fansidar* alone for 24 months (group B) and 1 was untreated (asymptomatic form diagnosed late at 9 months of life). Neonates with confirmed CT were given pyrimethamine (1.25 mg/kg every 10 days) and sulfadoxine (25 mg/kg every 10 days) in combination (Fansidar*, orally) with folinic acid supplementation every 7 days orally, as previously described. They were hematologically monitored once a month 3 None of Lyell or Stevens-Johnson syndrome was observed during this period, but just a mild transient skin rash in 1 child (group A). In 50% of cases, a moderate neutropenia (always >500/mm ) were observed. For this one, treatment was started at birth leading a neutropenia <500/mm 3 at 2 months of life ruling therapeutic, then Fansidar* was reintroduced after with neutropenia reappearance leading to a definitive stopping of the treatment at 3 months of life.
In order to measure compliance of treatment, pharmacological tests were done in sera to determine pyrimethamine and sulfadoxine levels as described previously 4, 5 Pyrimethamine and sulfadoxine assays in serum were possible in 78 children only from group B, 8 among these children had insufficient levels of drugs: a bad observance was reported in 2 children, 1 child had a reflux gastroesophageal, and posology was incorrect for 5 children. From these, the levels of drugs measured in serum were corrected after increase of therapeutic concentrations without adverse event.
So we are totally agree to the conclusion of this work and that sulfadoxine-pyrimethamine combination is welltolerated even if the children are treated from birth.
